tldrdailynews.com logo

Astellas acquires Iveric Bio for $5.9B in cash.

1 min read
Source: Endpoints News
Astellas acquires Iveric Bio for $5.9B in cash.
Photo: Endpoints News
TL;DR

Astellas Pharma has announced its acquisition of Iveric Bio for $5.9 billion in cash, as the Tokyo-based drugmaker prepares for a potential showdown with Apellis Pharmaceuticals in geographic atrophy. The deal comes amid a string of buyouts by Big Pharmas in recent weeks, as they hunt for late-stage drug candidates to boost their aging pipelines.

Topics:businessmergers-and-acquisitions#astellas#biotech#iveric-bio#mergers-and-acquisitions#pfizer#sanofi
Share this article
  1. Astellas to buy Iveric Bio for $5.9B in cash as biotech awaits August FDA nod in retinal disease  Endpoints News
  2. Astellas Enters into Definitive Agreement to Acquire Iveric Bio  PR Newswire
  3. Astellas Pharma buys Iveric Bio for $5.9 billion  Reuters
  4. Iveric Bio (NASDAQ:ISEE) Sold for $5.9B  TipRanks
  5. Iveric Bio Agrees to $5.9 Billion Bid From Astellas. The Stock Is Surging.  Barron's

Want the full story? Read the original reporting

Read on Endpoints News